Relay Therapeutics announced that it has commenced an underwritten public offering of $200M of shares of its common stock. All of the shares in the proposed offering are to be sold by Relay Therapeutics. Goldman Sachs & Co., TD Cowen, Stifel and BofA Securities are acting as joint book-running managers for the proposed offering. Raymond James is acting as co-manager.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $17 from $14 at Barclays
- Palantir, Dell Technologies named to join S&P 500: Morning Buzz
- Relay Therapeutics’ RLY-2608 Shows Promise in Breast Cancer Trials
- Relay Therapeutics PI3K data exceeds expectations, says Barclays
- Relay Therapeutics announces anticipated RLY-2608 next steps